BUDESONIDE

Indications

• Asthma
• Chronic obstructive pulmonary disease (COPD)
• Allergic rhinitis
• Inflammatory bowel disease (IBD)
• Eosinophilic esophagitis

Dosage

Children: Refer to the BNF for Children for age-specific dosing recommendations.

Adults: Refer to specific guidelines based on indication, typically starting with a low dose and titrating based on clinical response.

Mechanism of action

Budesonide exerts its therapeutic effects by binding to glucocorticoid receptors, leading to the transcription of anti-inflammatory proteins and the inhibition of pro-inflammatory cytokines. This results in decreased airway inflammation, reduced mucus secretion, and improved airflow in patients with respiratory conditions.

Pharmacodynamics

Budesonide demonstrates a potent anti-inflammatory effect, primarily by inhibiting the release of inflammatory mediators, such as leukotrienes and prostaglandins. This action helps to decrease bronchial hyperresponsiveness, which is a hallmark of asthma and other respiratory disorders. The onset of action is generally within hours, with peak effect observed within a few days of consistent use.

Pharmacokinetics

Budesonide is rapidly absorbed after inhalation or oral administration, with a bioavailability of approximately 10-20% due to extensive first-pass metabolism in the liver. The drug is metabolized primarily by the cytochrome P450 system (CYP3A4), and its elimination half-life is around 2 to 3 hours. The majority of the drug is excreted in urine as metabolites, with less than 1% excreted unchanged.

Contra-indications

• Hypersensitivity to budesonide or any of its components
• Untreated systemic fungal infections

Adverse effects

• Headache
• Nausea
• Vomiting
• Dizziness
• Increased risk of infections
• Cushing's syndrome (with long-term use)
• Osteoporosis (with prolonged therapy)
• Skin thinning and easy bruising

Interactions

• May interact with strong CYP3A4 inhibitors, increasing the risk of systemic effects
• Concomitant use with other corticosteroids can increase side effects

Precautions

• Use with caution in patients with a history of tuberculosis
• Monitor for signs of adrenal insufficiency
• Consider potential effects on growth in children
• Use cautiously in patients with cardiovascular disease

Pregnancy

Budesonide is classified as a Category B drug. Limited data suggests no increased risk of congenital malformations, but caution is advised.

Breast-feeding

Budesonide is excreted in breast milk, but at low concentrations. The benefits should be weighed against potential risks.

Storage

Store at room temperature, away from moisture and heat. Do not freeze.

Formulations

• Inhalation aerosol
• Nebulizing solution
• Oral extended-release capsules
• Nasal spray